In recent years, research based on embryonic stem cells has led to a great deal of controversy. However, increasingly, researchers are finding techniques that may allow them to turn average cells into cells with the characteristics of embryonic stem cells, something that could theoretically offer the benefits of stem cell research without the controversy. Now, drugmaker Pfizer has announced that it's getting into this game, opening a "regenerative medicine unit" in Cambridge, MA that will attempt to use these techniques. Article